{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-219420","form_type":"8-K","ticker":"ATRA","cik":"0001604464","company_name":"Atara Biotherapeutics, Inc.","filed_at":"2026-05-12T20:10:15+00:00","discovered_at":"2026-05-12T20:11:00.300712+00:00","generated_at":"2026-05-12T21:12:01.958888+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Q1 2026 net loss $4.1M; cash runway extended; FDA agrees path for tab-cel BLA resubmission","bullets":["Net loss $4.1M ($0.29 diluted EPS) vs net income $38.0M ($3.50 diluted) in Q1 2025.","Revenue $0.5M (prior Q1: $98.1M) due to FY2025 one-time tab-cel manufacturing transfer revenue.","Cash $8.4M at Mar 31; plus $4.8M ATM proceeds post-quarter; runway into mid-2027.","FDA agreed single-arm ALLELE study with historical control could support tab-cel BLA resubmission; update expected Q3 2026.","R&D expenses $0.2M (vs $27.4M), G&A $3.6M (vs $11.5M) reflecting cost reductions."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-219420","json":"https://secwatch.observer/filing/0001193125-26-219420.json","markdown":"https://secwatch.observer/filing/0001193125-26-219420.md","text":"https://secwatch.observer/filing/0001193125-26-219420.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1604464/000119312526219420/0001193125-26-219420-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1604464/000119312526219420/atra-20260512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-12T21:12:01.958888+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6b54b84069164cee33291b27eaaa98e4f58e360d","claim":"Atara Biotherapeutics, Inc. reported first quarter 2026 results: revenue $0.5 million, net income net loss of $4.1 million, EPS ($0.29) basic and diluted loss per share.","evidence_excerpt":"31, 2025. • Net cash used in operating activities was $3.1 million for the first quarter 2026, as compared to $28.1 million in the same period in 2025. • Total revenues were $0.5 million for the first quarter 2026, as compared to $98.1 million for the same period in 2025. The prior ‐ year period reflects a one ‐ time acceleration of revenue recognized upon the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1604464/000119312526219420/0001193125-26-219420-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter 2026"},{"label":"Revenue","value":"$0.5 million"},{"label":"Net income","value":"net loss of $4.1 million"},{"label":"EPS","value":"($0.29) basic and diluted loss per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}